Teicoplanin

Multidrug-resistant bacterial infection is the core challenge of global clinical anti-infective therapy at present. As an important member of glycopeptide antibiotics, teicoplanin exerts a bactericidal effect by inhibiting the synthesis of bacterial cell walls, and has strong antibacterial activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) and other multidrug-resistant strains. It is clinically mainly used for the treatment of lower respiratory tract infections, skin and soft tissue infections, sepsis, endocarditis and peritoneal dialysis-related peritonitis caused by sensitive bacteria, and can also be used as prophylactic medication for neutropenic patients at high risk of Gram-positive bacterial infections, applicable to adult and pediatric populations. Its clinical characteristic of lower nephrotoxicity than vancomycin provides a safer option for patients requiring long-term anti-infective treatment.

At present, the global teicoplanin market size is approximately USD 1.2 billion, with a compound annual growth rate of around 4.2%. The Chinese market accounts for about 31%, making it one of the fastest-growing regional markets. The domestic competitive landscape is characterized by the dominance of generic drugs. Teicoplanin preparations from more than 8 enterprises have been approved for marketing. After being included in the national centralized drug procurement in 2022, the average price reduction of winning bids reached 68%, and the clinical penetration rate increased from 17% before the centralized procurement to 32% in 2024, directly driving the continuous expansion of upstream API demand. At present, domestic API manufacturers are mainly local enterprises, and the overall production capacity can meet the demand of domestic preparation production and part of export demand.

The original research enterprise of teicoplanin is Sanofi, and the original research brand name is Targocid. Its core compound patents expired in Europe in 2003 and in the United States in 2004 respectively, and the Chinese compound patent expired in 2002. The main dosage form of the original research product is teicoplanin for injection, with two marketed specifications of 0.2g and 0.4g. The original research preparation has been included in the *Catalogue of Reference Preparations of Chemical Drugs* of China, and is also included in the FDA Reference Preparation Catalogue. Up to now, there are 17 teicoplanin API registration entries on the CDE API Registration Platform, of which 12 have obtained status A (marketable), and 11 domestic enterprises have had their teicoplanin injections approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of teicoplanin impurity reference standards, covering the full research sequence including process impurities and degradation impurities, which can match the whole-process quality control requirements from API synthesis process optimization to preparation stability research. Most products are available from stock. In-stock products ordered before 16:00 will be shipped on the same day. All reference standards meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable material basis support for enterprises to shorten the R&D cycle and reduce declaration risks.